RTW Biotech Opportunities (LON:RTW – Get Free Report)’s stock price reached a new 52-week high on Wednesday . The company traded as high as GBX 2.49 and last traded at GBX 2.48, with a volume of 214529 shares traded. The stock had previously closed at GBX 2.44.
RTW Biotech Opportunities Price Performance
The company has a debt-to-equity ratio of 20.05, a quick ratio of 0.81 and a current ratio of 0.15. The stock’s fifty day moving average price is GBX 2.28 and its 200-day moving average price is GBX 2.17. The firm has a market cap of £8.00 million, a PE ratio of 0.04 and a beta of 1.23.
RTW Biotech Opportunities Company Profile
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Bio invests in companies developing next-generation therapies and technologies that can significantly improve patients’ lives. RTW Bio is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Featured Stories
- Five stocks we like better than RTW Biotech Opportunities
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for RTW Biotech Opportunities Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTW Biotech Opportunities and related companies with MarketBeat.com's FREE daily email newsletter.
